TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A [440-779](Human)
H. Lundbeck
US Patent
H. Lundbeck
US Patent
Affinity DataIC50: 0.330nMT: 25°CAssay Description:The assay is performed in 60 uL samples containing a fixed amount of the relevant PDE enzyme (sufficient to convert 20-25% of the cyclic nucleotide s...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A [440-779](Human)
H. Lundbeck
US Patent
H. Lundbeck
US Patent
Affinity DataIC50: 0.390nMT: 25°CAssay Description:The assay is performed in 60 uL samples containing a fixed amount of the relevant PDE enzyme (sufficient to convert 20-25% of the cyclic nucleotide s...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A [440-779](Human)
H. Lundbeck
US Patent
H. Lundbeck
US Patent
Affinity DataIC50: 0.400nMT: 25°CAssay Description:The assay is performed in 60 uL samples containing a fixed amount of the relevant PDE enzyme (sufficient to convert 20-25% of the cyclic nucleotide s...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A [440-779](Human)
H. Lundbeck
US Patent
H. Lundbeck
US Patent
Affinity DataIC50: 0.440nMT: 25°CAssay Description:The assay is performed in 60 uL samples containing a fixed amount of the relevant PDE enzyme (sufficient to convert 20-25% of the cyclic nucleotide s...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A [440-779](Human)
H. Lundbeck
US Patent
H. Lundbeck
US Patent
Affinity DataIC50: 0.520nMT: 25°CAssay Description:The assay is performed in 60 uL samples containing a fixed amount of the relevant PDE enzyme (sufficient to convert 20-25% of the cyclic nucleotide s...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A [440-779](Human)
H. Lundbeck
US Patent
H. Lundbeck
US Patent
Affinity DataIC50: 0.540nMT: 25°CAssay Description:The assay is performed in 60 uL samples containing a fixed amount of the relevant PDE enzyme (sufficient to convert 20-25% of the cyclic nucleotide s...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A [440-779](Human)
H. Lundbeck
US Patent
H. Lundbeck
US Patent
Affinity DataIC50: 0.550nMT: 25°CAssay Description:The assay is performed in 60 uL samples containing a fixed amount of the relevant PDE enzyme (sufficient to convert 20-25% of the cyclic nucleotide s...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A [440-779](Human)
H. Lundbeck
US Patent
H. Lundbeck
US Patent
Affinity DataIC50: 0.990nMT: 25°CAssay Description:The assay is performed in 60 uL samples containing a fixed amount of the relevant PDE enzyme (sufficient to convert 20-25% of the cyclic nucleotide s...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A [440-779](Human)
H. Lundbeck
US Patent
H. Lundbeck
US Patent
Affinity DataIC50: 1nMT: 25°CAssay Description:The assay is performed in 60 uL samples containing a fixed amount of the relevant PDE enzyme (sufficient to convert 20-25% of the cyclic nucleotide s...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A [440-779](Human)
H. Lundbeck
US Patent
H. Lundbeck
US Patent
Affinity DataIC50: 1.10nMT: 25°CAssay Description:The assay is performed in 60 uL samples containing a fixed amount of the relevant PDE enzyme (sufficient to convert 20-25% of the cyclic nucleotide s...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A [440-779](Human)
H. Lundbeck
US Patent
H. Lundbeck
US Patent
Affinity DataIC50: 1.20nMT: 25°CAssay Description:The assay is performed in 60 uL samples containing a fixed amount of the relevant PDE enzyme (sufficient to convert 20-25% of the cyclic nucleotide s...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A [440-779](Human)
H. Lundbeck
US Patent
H. Lundbeck
US Patent
Affinity DataIC50: 1.29nMT: 25°CAssay Description:The assay is performed in 60 uL samples containing a fixed amount of the relevant PDE enzyme (sufficient to convert 20-25% of the cyclic nucleotide s...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A [440-779](Human)
H. Lundbeck
US Patent
H. Lundbeck
US Patent
Affinity DataIC50: 1.5nMT: 25°CAssay Description:The assay is performed in 60 uL samples containing a fixed amount of the relevant PDE enzyme (sufficient to convert 20-25% of the cyclic nucleotide s...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A [440-779](Human)
H. Lundbeck
US Patent
H. Lundbeck
US Patent
Affinity DataIC50: 1.70nMT: 25°CAssay Description:The assay is performed in 60 uL samples containing a fixed amount of the relevant PDE enzyme (sufficient to convert 20-25% of the cyclic nucleotide s...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A [440-779](Human)
H. Lundbeck
US Patent
H. Lundbeck
US Patent
Affinity DataIC50: 1.70nMT: 25°CAssay Description:The assay is performed in 60 uL samples containing a fixed amount of the relevant PDE enzyme (sufficient to convert 20-25% of the cyclic nucleotide s...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A [440-779](Human)
H. Lundbeck
US Patent
H. Lundbeck
US Patent
Affinity DataIC50: 2.30nMT: 25°CAssay Description:The assay is performed in 60 uL samples containing a fixed amount of the relevant PDE enzyme (sufficient to convert 20-25% of the cyclic nucleotide s...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A [440-779](Human)
H. Lundbeck
US Patent
H. Lundbeck
US Patent
Affinity DataIC50: 2.70nMT: 25°CAssay Description:The assay is performed in 60 uL samples containing a fixed amount of the relevant PDE enzyme (sufficient to convert 20-25% of the cyclic nucleotide s...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A [440-779](Human)
H. Lundbeck
US Patent
H. Lundbeck
US Patent
Affinity DataIC50: 2.70nMT: 25°CAssay Description:The assay is performed in 60 uL samples containing a fixed amount of the relevant PDE enzyme (sufficient to convert 20-25% of the cyclic nucleotide s...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A [440-779](Human)
H. Lundbeck
US Patent
H. Lundbeck
US Patent
Affinity DataIC50: 2.80nMT: 25°CAssay Description:The assay is performed in 60 uL samples containing a fixed amount of the relevant PDE enzyme (sufficient to convert 20-25% of the cyclic nucleotide s...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A [440-779](Human)
H. Lundbeck
US Patent
H. Lundbeck
US Patent
Affinity DataIC50: 2.90nMT: 25°CAssay Description:The assay is performed in 60 uL samples containing a fixed amount of the relevant PDE enzyme (sufficient to convert 20-25% of the cyclic nucleotide s...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A [440-779](Human)
H. Lundbeck
US Patent
H. Lundbeck
US Patent
Affinity DataIC50: 3.10nMT: 25°CAssay Description:The assay is performed in 60 uL samples containing a fixed amount of the relevant PDE enzyme (sufficient to convert 20-25% of the cyclic nucleotide s...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A [440-779](Human)
H. Lundbeck
US Patent
H. Lundbeck
US Patent
Affinity DataIC50: 3.40nMT: 25°CAssay Description:The assay is performed in 60 uL samples containing a fixed amount of the relevant PDE enzyme (sufficient to convert 20-25% of the cyclic nucleotide s...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A [440-779](Human)
H. Lundbeck
US Patent
H. Lundbeck
US Patent
Affinity DataIC50: 4nMT: 25°CAssay Description:The assay is performed in 60 uL samples containing a fixed amount of the relevant PDE enzyme (sufficient to convert 20-25% of the cyclic nucleotide s...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A [440-779](Human)
H. Lundbeck
US Patent
H. Lundbeck
US Patent
Affinity DataIC50: 4nMT: 25°CAssay Description:A PDE10A assay may for example, be performed as follows: The assay is performed in 60 uL samples containing a fixed amount of the relevant PDE enzyme...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A [440-779](Human)
H. Lundbeck
US Patent
H. Lundbeck
US Patent
Affinity DataIC50: 4.10nMT: 25°CAssay Description:The assay is performed in 60 uL samples containing a fixed amount of the relevant PDE enzyme (sufficient to convert 20-25% of the cyclic nucleotide s...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A [440-779](Human)
H. Lundbeck
US Patent
H. Lundbeck
US Patent
Affinity DataIC50: 4.20nMT: 25°CAssay Description:The assay is performed in 60 uL samples containing a fixed amount of the relevant PDE enzyme (sufficient to convert 20-25% of the cyclic nucleotide s...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A [440-779](Human)
H. Lundbeck
US Patent
H. Lundbeck
US Patent
Affinity DataIC50: 4.20nMT: 25°CAssay Description:The assay is performed in 60 uL samples containing a fixed amount of the relevant PDE enzyme (sufficient to convert 20-25% of the cyclic nucleotide s...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A [440-779](Human)
H. Lundbeck
US Patent
H. Lundbeck
US Patent
Affinity DataIC50: 4.5nMT: 25°CAssay Description:The assay is performed in 60 uL samples containing a fixed amount of the relevant PDE enzyme (sufficient to convert 20-25% of the cyclic nucleotide s...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A [440-779](Human)
H. Lundbeck
US Patent
H. Lundbeck
US Patent
Affinity DataIC50: 5.70nMT: 25°CAssay Description:The assay is performed in 60 uL samples containing a fixed amount of the relevant PDE enzyme (sufficient to convert 20-25% of the cyclic nucleotide s...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A [440-779](Human)
H. Lundbeck
US Patent
H. Lundbeck
US Patent
Affinity DataIC50: 5.70nMT: 25°CAssay Description:The assay is performed in 60 uL samples containing a fixed amount of the relevant PDE enzyme (sufficient to convert 20-25% of the cyclic nucleotide s...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A [440-779](Human)
H. Lundbeck
US Patent
H. Lundbeck
US Patent
Affinity DataIC50: 5.70nMT: 25°CAssay Description:The assay is performed in 60 uL samples containing a fixed amount of the relevant PDE enzyme (sufficient to convert 20-25% of the cyclic nucleotide s...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A [440-779](Human)
H. Lundbeck
US Patent
H. Lundbeck
US Patent
Affinity DataIC50: 6.40nMT: 25°CAssay Description:The assay is performed in 60 uL samples containing a fixed amount of the relevant PDE enzyme (sufficient to convert 20-25% of the cyclic nucleotide s...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A [440-779](Human)
H. Lundbeck
US Patent
H. Lundbeck
US Patent
Affinity DataIC50: 6.80nMT: 25°CAssay Description:The assay is performed in 60 uL samples containing a fixed amount of the relevant PDE enzyme (sufficient to convert 20-25% of the cyclic nucleotide s...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A [440-779](Human)
H. Lundbeck
US Patent
H. Lundbeck
US Patent
Affinity DataIC50: 6.80nMT: 25°CAssay Description:The assay is performed in 60 uL samples containing a fixed amount of the relevant PDE enzyme (sufficient to convert 20-25% of the cyclic nucleotide s...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A [440-779](Human)
H. Lundbeck
US Patent
H. Lundbeck
US Patent
Affinity DataIC50: 6.90nMT: 25°CAssay Description:The assay is performed in 60 uL samples containing a fixed amount of the relevant PDE enzyme (sufficient to convert 20-25% of the cyclic nucleotide s...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A [440-779](Human)
H. Lundbeck
US Patent
H. Lundbeck
US Patent
Affinity DataIC50: 7.40nMT: 25°CAssay Description:A PDE10A assay may for example, be performed as follows: The assay is performed in 60 uL samples containing a fixed amount of the relevant PDE enzyme...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A [440-779](Human)
H. Lundbeck
US Patent
H. Lundbeck
US Patent
Affinity DataIC50: 7.5nMT: 25°CAssay Description:The assay is performed in 60 uL samples containing a fixed amount of the relevant PDE enzyme (sufficient to convert 20-25% of the cyclic nucleotide s...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A [440-779](Human)
H. Lundbeck
US Patent
H. Lundbeck
US Patent
Affinity DataIC50: 7.60nMT: 25°CAssay Description:The assay is performed in 60 uL samples containing a fixed amount of the relevant PDE enzyme (sufficient to convert 20-25% of the cyclic nucleotide s...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A [440-779](Human)
H. Lundbeck
US Patent
H. Lundbeck
US Patent
Affinity DataIC50: 7.90nMT: 25°CAssay Description:The assay is performed in 60 uL samples containing a fixed amount of the relevant PDE enzyme (sufficient to convert 20-25% of the cyclic nucleotide s...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A [440-779](Human)
H. Lundbeck
US Patent
H. Lundbeck
US Patent
Affinity DataIC50: 8.40nMT: 25°CAssay Description:The assay is performed in 60 uL samples containing a fixed amount of the relevant PDE enzyme (sufficient to convert 20-25% of the cyclic nucleotide s...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A [440-779](Human)
H. Lundbeck
US Patent
H. Lundbeck
US Patent
Affinity DataIC50: 8.80nMT: 25°CAssay Description:The assay is performed in 60 uL samples containing a fixed amount of the relevant PDE enzyme (sufficient to convert 20-25% of the cyclic nucleotide s...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A [440-779](Human)
H. Lundbeck
US Patent
H. Lundbeck
US Patent
Affinity DataIC50: 8.80nMT: 25°CAssay Description:The assay is performed in 60 uL samples containing a fixed amount of the relevant PDE enzyme (sufficient to convert 20-25% of the cyclic nucleotide s...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A [440-779](Human)
H. Lundbeck
US Patent
H. Lundbeck
US Patent
Affinity DataIC50: 8.80nMT: 25°CAssay Description:A PDE10A assay may for example, be performed as follows: The assay is performed in 60 uL samples containing a fixed amount of the relevant PDE enzyme...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A [440-779](Human)
H. Lundbeck
US Patent
H. Lundbeck
US Patent
Affinity DataIC50: 8.80nMT: 25°CAssay Description:The assay is performed in 60 uL samples containing a fixed amount of the relevant PDE enzyme (sufficient to convert 20-25% of the cyclic nucleotide s...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A [440-779](Human)
H. Lundbeck
US Patent
H. Lundbeck
US Patent
Affinity DataIC50: 8.90nMT: 25°CAssay Description:The assay is performed in 60 uL samples containing a fixed amount of the relevant PDE enzyme (sufficient to convert 20-25% of the cyclic nucleotide s...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A [440-779](Human)
H. Lundbeck
US Patent
H. Lundbeck
US Patent
Affinity DataIC50: 9.20nMT: 25°CAssay Description:The assay is performed in 60 uL samples containing a fixed amount of the relevant PDE enzyme (sufficient to convert 20-25% of the cyclic nucleotide s...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A [440-779](Human)
H. Lundbeck
US Patent
H. Lundbeck
US Patent
Affinity DataIC50: 9.20nMT: 25°CAssay Description:The assay is performed in 60 uL samples containing a fixed amount of the relevant PDE enzyme (sufficient to convert 20-25% of the cyclic nucleotide s...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A [440-779](Human)
H. Lundbeck
US Patent
H. Lundbeck
US Patent
Affinity DataIC50: 9.60nMT: 25°CAssay Description:The assay is performed in 60 uL samples containing a fixed amount of the relevant PDE enzyme (sufficient to convert 20-25% of the cyclic nucleotide s...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A [440-779](Human)
H. Lundbeck
US Patent
H. Lundbeck
US Patent
Affinity DataIC50: 9.60nMT: 25°CAssay Description:The assay is performed in 60 uL samples containing a fixed amount of the relevant PDE enzyme (sufficient to convert 20-25% of the cyclic nucleotide s...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A [440-779](Human)
H. Lundbeck
US Patent
H. Lundbeck
US Patent
Affinity DataIC50: 9.60nMT: 25°CAssay Description:The assay is performed in 60 uL samples containing a fixed amount of the relevant PDE enzyme (sufficient to convert 20-25% of the cyclic nucleotide s...More data for this Ligand-Target Pair